Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study

被引：1
|
作者：
Li, B-K. [1 ]
Yuan, Y. [1 ]
Qiao, L. [1 ]
He, W. [1 ]
Wang, G. [2 ]
Chen, H. [3 ]
Zhang, B. [4 ]
Fuxi, H. [5 ]
Qiu, J. [1 ]
机构：
[1] Sun Yat Sen Univ, Dept Liver Surg, Canc Ctr, Guangzhou, Peoples R China
[2] Guangzhou Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Guangzhou, Peoples R China
[3] First Peoples Hosp Foshan, Dept Hepat Surg, Foshan, Peoples R China
[4] Guangzhou Panyu Dist He Xian Mem Hosp, Dept Oncol, Guangzhou, Peoples R China
[5] Panyu Cent Hosp, Canc Inst Panyu, Dept Oncol, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2095
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
949P
引用
收藏
页码：S596 / S596
页数：1
相关论文
共 50 条
  • [21] Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching
    Xavier Adhoute
    Marie De Matharel
    Laurent Mineur
    Guillaume Pénaranda
    Dann Ouizeman
    Clemence Toullec
    Albert Tran
    Paul Castellani
    Armelle Rollet
    Valérie Oules
    Hervé Perrier
    Si Nafa Si Ahmed
    Marc Bourliere
    Rodolphe Anty
    World Journal of Gastrointestinal Oncology, 2022, (08) : 1510 - 1527
  • [22] Regorafenib promising second-line treatment in hepatocellular carcinoma
    不详
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2016, 77 (08) : 446 - 446
  • [23] Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching
    Adhoute, Xavier
    De Matharel, Marie
    Mineur, Laurent
    Penaranda, Guillaume
    Ouizeman, Dann
    Toullec, Clemence
    Tran, Albert
    Castellani, Paul
    Rollet, Armelle
    Oules, Valerie
    Perrier, Herve
    Ahmed, Si Nafa Si
    Bourliere, Marc
    Anty, Rodolphe
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 14 (08) : 1510 - 1527
  • [24] Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
    Han, Yue
    Cao, Guang
    Sun, Bin
    Wang, Jian
    Yan, Dong
    Xu, Haifeng
    Shi, Qinsheng
    Liu, Zechuan
    Zhi, Weihua
    Xu, Liang
    Liu, Bojun
    Zou, Yinghua
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [25] Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
    Yue Han
    Guang Cao
    Bin Sun
    Jian Wang
    Dong Yan
    Haifeng Xu
    Qinsheng Shi
    Zechuan Liu
    Weihua Zhi
    Liang Xu
    Bojun Liu
    Yinghua Zou
    BMC Gastroenterology, 21
  • [26] Efficacy and safety of regorafenib alone or in combinations for advanced hepatocellular carcinoma: A multicenter real-world study.
    Zhu, Haidong
    Zhu, Xiaoli
    Song, Yusheng
    Wang, Qi
    Wu, Jianbing
    Xu, Hao
    Teng, Gaojun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16122 - E16122
  • [27] Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
    Trojan, Joerg
    Waidmann, Oliver
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2016, 3 : 31 - 36
  • [28] Regorafenib combined with PD-1 monoclonal antibody in the second-line setting for hepatocellular carcinoma (HCC): A retrospective, real-world study in China.
    Li, Zhongchao
    Li, Lei
    Zhong, Jingtao
    Cui, Kai
    Zhang, Chengsheng
    Shi, Xuetao
    Sun, Pengfei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16145 - E16145
  • [29] A nationwide multicenter study of Japanese patients with unresectable hepatocellular carcinoma treated with regorafenib in real-world practice
    Tsuchiya, Kaoru
    Kurosaki, Masayuki
    Sakamoto, Azusa
    Matusawa, Hiroyuki
    Hasebe, Chitomi
    Abe, Takehiko
    Joko, Kouji
    Ogawa, Chikara
    Furuta, Koichiro
    Kusakabe, Atsunori
    Kobashi, Haruhiko
    Kimura, Hiroyuki
    Matsushita, Tomomichi
    Uchida, Yasushi
    Izumi., Namiki
    JOURNAL OF HEPATOLOGY, 2020, 73 : S911 - S911
  • [30] Effectiveness of regorafenib in second-line therapy for advanced hepatocellular carcinoma A systematic review and meta-analysis
    Shen, Yunzhi
    Bai, Yu
    MEDICINE, 2025, 104 (04)
12345